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Amberly Nicole Grothe 
IDENTIFYING FACTORS CONTROLLING CELL SHAPE AND VIRULENCE GENE 
EXPRESSION IN BORRELIA BURGDORFERI 
Lyme disease is a multi-system inflammatory disorder that is currently the fastest 
growing arthropod-borne disease in the United States. The Lyme disease pathogen, 
Borrelia burgdorferi, exists within an enzootic cycle consisting of Ixodes tick vectors and 
a variety of vertebrate hosts. Borrelia lies within a distinct clade of microorganisms 
known as spirochetes which exhibit a unique spiral morphology. The underlying genetic 
mechanisms controlling for borrelial morphologies are still being discovered. One 
flagellar protein, FlaB, has been indicated to affect both spiral shape and motility of the 
organisms and significantly impacts the organism’s ability to establish infection. Due to 
the potential connection between morphological characteristics and pathogenesis, we 
sought to screen and identify morphological mutants in an attempt to identify genes 
associated with morphological phenotypes of Borrelia burgdorferi. 
Among Borrelia’s unique features is the presence of abundant lipoproteins making up 
its cellular membrane as opposed to the typical lipopolysaccharides. These proteins 
confer a wide variety of functions to the microorganism, among which include the 
abilities to circulate between widely differing hosts and to establish infection. Two 
important outer surface proteins, OspC and OspA, are found to be inversely expressed 
throughout the borrelial life cycle. OspC, in particular, becomes highly expressed during 
tick-feeding and transmission to the mammalian host. It has been found to be essential for 
establishment of infection. A global regulatory pathway has been shown to control for 
OspC, however there are missing links in this pathway between the external stimuli (such 
vi 
as temperature, pH, and cell density) and the regulatory pathway. We have performed a 
screening process to identify OspC expression mutants in order to identify novel genes 
associated with this pathway. 
X. Frank Yang, Ph.D. - Chair 
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INTRODUCTION 
Lyme Disease History 
Lyme disease is a multi-system inflammatory disorder that is currently the fastest 
growing vector-borne disease in the U.S. Lyme disease was initially recognized in Lyme, 
Connecticut in 1976 when a large incidence of children was found exhibiting symptoms 
of juvenile arthritis. The occurrence of the characteristic bulls-eye rash now associated 
with Lyme disease was apparent in 25% percent of the cases (Steere et al, 1977). This led 
to an investigation of the disease, with the hypothesis that it was caused by an infectious 
agent. Due to the increased prevalence of this disease in rural, wooded areas, it was 
further hypothesized that the clinical agent may be transmitted via an arthropod vector 
(Steere et al, 1978). Six years later, in 1982, spirochetal bacteria were isolated from the 
midgut of an Ixodes tick by Willy Burgdorfer and his research team. At this point, 
Borrelia burgdorferi was identified as the disease-causing pathogen (Burgdorfer et al, 
1982). 
The principal species responsible for infection in the US is Ixodes scapularis, 
formerly known as Ixodes dammini, which is responsible for the transmission of disease 
in the Northeastern and Upper Midwestern regions of the U.S. Milder forms of Lyme 
disease may be found on the western coast, which are caused by Ixodes pacificus 
(Schmid, 1985) (Figure 1.1A, 1.1B). A dramatic geographical expansion of reported 
Lyme disease cases, particularly in the Northeast and Midwestern regions, can be seen in 
Figures 1.1A and 1.1B. Lyme disease also occurs in Europe and parts of Asia and Africa, 
with I. persulcatus the major tick vector in Eastern Europe and Asia and I. ricinus a 
major vector in Northern Europe and Africa (Gray, 1998).  
2 
The initial incidence of Lyme disease in the United States was low but as knowledge 
of the disease expanded and detection methods improved, the reports of the disease have 
markedly increased. Lyme disease became a reportable disease in the U.S. in 1991 with 
an original incidence of 9465 cases per year. Over the last 30 years, incidence rates have 
nearly tripled with approximately 30,000 confirmed cases in 2017 (Figure 1.1C). 
Additionally, two studies performed by the CDC suggest that that Lyme disease 
diagnoses may be closer to 300,000 per year (CDC, 2018). 
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Figure 1.1: Incidence of Lyme Disease from 1997 to 2017 
A, geographical incidence of Lyme Disease by county of residence in 2001. B, 
geographical incidence of Lyme Disease by county of residence in 2017. C, confirmed 
and probable cases reported per year to CDC from 1997 to 2017.  
Source: CDC Lyme disease maps – Historical data; CDC Lyme disease chart and figures 
– Historical data  
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Stages, Symptoms, and Treatments 
There are three defined stages of the infection. The initial stage of the disease is 
characterized by a localized infection found at the site of the tick bite. This stage typically 
presents as a characteristic bulls-eye rash, known as erythema migrans (EM) and flu-like 
symptoms. The next stage of the infection is disseminated infection, which occurs when 
the bacteria has spread to the circulatory system.  Symptoms of this stage include 
secondary erythema migrans, which arises in areas of the body unassociated with tick bite 
site, and flu-like symptoms. If left untreated, Borrelia can localize into many different 
organs throughout the body. This stage is referred to as late or persistent infection and 
most commonly results in Lyme arthritis (Wright et al, 2012). However, rarer and more 
severe symptoms can occur such as myocarditis and neuroencephalitis (Burgdorfer, 1991; 
CDC, 2018; Cooke and Dattwyler, 1992; Steere, 2001; Steere et al, 2004).  
Treatment is available for Lyme disease. This is typically an intense antibiotic 
regimen consisting of Doxycycline, Amoxicillin, and/or Cefuroxime axetil. Antibiotics 
usually are taken for several weeks/months (CDC, 2018). However, another rare stage 
can occur, known as Post-Treatment Lyme Disease syndrome or Chronic Lyme disease, 
in which recurring Lyme disease symptoms appear in patients who have already 
undergone Lyme disease treatment (Marques, 2008; Steere et al, 2004). Little is known 
about this syndrome and studies are currently being done to understand it. 
 
Phylum Spirochaetes and the Borrelia genus 
Borrelia burgdorferi lies within the family Spirochaetes, a unique and 
phylogenetically distinct group of bacteria. This family contains the well-known 
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pathogens Treponema pallidum, the causative agent of syphilis, and Leptospira 
interrogans, the causative agent of leptospirosis (McBride et al, 2005; Radolf, 1996; 
Tilly et al, 2007). The most distinctive feature of this group of bacteria is their spiral or 
wavelike morphology (Tilly et al, 2007). This spiral morphology is believed to confer 
increased speed and motility for the bacteria and allow for movement within more 
viscous environments (Motaleb et al, 2015; Yang et al, 2016). The bacteria within this 
family are also interesting because they are extremely invasive but contain little to no 
known toxins (Fraser et al, 1997; Hyde et al, 2011a). Based on this, it is believed that the 
pathogenesis is due to bacterial burden and the host immune response rather than 
bacterial toxicity (Fraser et al, 1997; Steere, 2001). 
Borrelia burgdorferi is a bloodborne, microaerophilic, obligate parasite. They can 
range from 4 to 30um in length and .2 to .3 um in helices width (Johnson et al, 1984; 
Barbour, 1986). They are considered gram-negative-like spirochetes due to their similar 
dual-membrane system. However, they differ widely from true gram-negative bacteria 
because they do not contain lipopolysaccharides in their membrane (Takayama et al, 
1987). Instead, they contain abundant lipoproteins (Fraser et al, 1997). Furthermore, they 
contain an endoflagella, as opposed to the typical external flagella, that resides in the 
periplasmic space and is attached to both ends of a protoplasmic cylinder. The flagella 
are composed of seven flagellar proteins that are wrapped around the protoplasmic 
cylinder, providing its unique spiral shape as well as its motility (Johnson, 1977; Barbour, 
1986; Sultan et al, 2013). B. burgdorferi also exist solely within an enzootic cycle 
featuring Ixodes ticks as the vector and small vertebrates, typically mammals and birds, 
as hosts (Radolf et al, 2012).  
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The Borrelia genome consists of 1 linear chromosome and up to 21 linear and circular 
plasmids, typically with 12 linear and 9 circular. The linear chromosome is 
approximately 910 kb in size while the plasmids range from 5 to 56 kb (Fraser et al, 
1997; Casjens et al, 2002). Only the linear chromosome and one circular plasmid, cp26, 
are essential for borrelial growth (Chaconas and Kobryn, 2010; Kobryn and Chaconas, 
2002); however, the plasmids cp26, cp32, lp25, lp28-1, and lp54 have been shown to be 
essential within the enzootic cycle (Labandeira-Rey and Skare, 2001; Purser et al, 2003; 
Stewart et al, 2004a)(Figure 1.2). Because several of the plasmids are not essential for 
basic borrelial growth, in vitro propagation can lead to spontaneous loss of some 
plasmids, which can make genetic work difficult (Rosa et al, 2005). While the entirety of 
the B. burgdorferi genome has been sequenced, approximately 30% of the chromosome 
and much of the plasmids shared no significant homology with any previously identified 
genes (Fraser et al, 1997; Brisson et al, 2012), indicating areas of interest for future 
genetic work for Borrelia. 
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Figure 1.2: Borrelia burgdorferi Strain B31 Genome. 
All plasmids from the B. burgdorferi strain B31 genome. All plasmids essential for 
virulence are indicated in red. The remaining plasmids are unessential for virulence, 
though the chromosome and cp26 are essential for survival, and are indicated in green. 
Source: Stewart et al, 2004a. 
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Borrelia Morphology 
Cell shape has been shown to contribute to bacterial pathogenesis. For instance, the 
curvature of Caulobacter crescentus was found to enhance colonization within aquatic 
environments with moderate flow in comparison to a rod-shaped version (Persat et al, 
2014). Flagella are also important contributors to an organism’s pathogenesis. Both the 
number and location of the flagella can affect the speed and the form of movement of a 
microbe, conferring a variety of potential advantages and disadvantages to its 
pathogenicity. For example, having multiple flagella may allow a pathogen to maneuver 
more quickly through its environment as opposed to a uniflagellar organism (Yang et al, 
2016). Spiral shapes are believed to allow greater motility and speed for bacteria in more 
viscous environments (Motaleb et al, 2015; Yang et al, 2016), which would be ideal for 
bloodborne pathogens such as B. burgdorferi. 
Since its discovery, many studies have attempted to understand the mechanisms 
responsible for the morphology of B. burgdorferi. Borrelia contains a bundle of 7 to 11 
periplasmic flagella that are wrapped around the protoplasmic cylinder and attached at 
the two ends of the protoplasmic cylinder (Barbour and Hayes, 1986; Charon and 
Goldstein, 2002). Due to its unique placement in the cell, the borrelial flagella is 
responsible for both cell shape and cell motility (Motaleb et al, 2000). This tight 
connection between cell shape and motility can make it difficult to identify genetic 
factors responsible for specific morphological characteristics. 
With advancement in genetic tools, parts of this morphological system have been 
elucidated. As of 2013, 24 genes had been identified associated with the flagella, 
chemotaxis, motility, or overall morphology gene regulation (Charon et al, 2012). FlaB, a 
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major flagellar filament protein, and FlaA, a minor flagellar filament protein, are 
important contributors to the flagellar makeup. FlaB in particular created straight rod 
phenotypes when mutated and was non-motile (Charon and Goldstein, 2002; Charon et 
al, 2012; Ge et al, 1998; Motaleb et al, 2000). Other genes important for imparting spiral 
shape and motility to the organism were flgE, fliF, and fliG2 (Charon and Goldstein, 
2002; Li et al, 2010; Sal et al, 2008). A carbon storage regulator gene, csrA, is 
responsible for repressing FlaB and causes straight rod phenotype and elongation of cells 
when overexpressed (Sze et al, 2012).  
B. burgdorferi also contain several copies of chemotaxis genes typically found in 
other bacteria, including 6 mcp, 2 cheA, 3 cheY, 2 cheB, 2 cheR, and 3 cheW genes 
(Charon et al, 2012; Fraser et al, 1997). Of these, the known borrelial chemotaxis 
pathway currently consists of MCPs, CheW3, CheA2, CheY3, and CheX. CheA2 
phosphorylates CheY3, a key chemotaxis response regulator, to form CheY3-P. CheX, 
identified as essential for chemotaxis, is responsible for dephosphorylating CheY3-P 
(Charon et al, 2012; Motaleb et al, 2005; Motaleb et al, 2011). Two genes, motA and 
motB, are responsible for forming part of the motor complex and are both essential for 
motility in B. burgdorferi (Sultan et al, 2015). 
A variety of other factors are involved in Borrelia morphology. Elongated cells can 
arise naturally when cells get old or when they are in nutritionally inadequate media 
(Barbour and Hayes, 1986). Several genes have been linked to a variety of other 
morphological phenotypes as well. CsrA mutants resulted in organisms that not only had 
flat-wave morphology but were elongated. The periplasmic flagella from these mutants 
were tightly bound to the protoplasmic cylinder and is a potential explanation for why 
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longer cells tend to have flat-wave shape with small wavelength and less amplitude (Sze 
et al, 2011; Charon et al, 2012). Hfq, a global regulatory RNA-binding protein, and 
DhhP, a DHH-DHHA binding protein, have both been implicated as elongation-causing 
mutants (Lybecker et al, 2010; Ye et al, 2014). 
While several plasmids have been noted as essential for virulence, only the 
chromosome and cp26 have been required for basic borrelial growth in vitro. Originally, 
only the resT gene was identified as essential for growth, as it was responsible for 
encoding the telomere resolvase gene (Byram et al, 2004). Hfq and DhhP have recently 
been shown to either significantly enhance borrelial growth or be essential for growth 
(Lybecker et al, 2010; Ye et al, 2014).  
B. burgdorferi has been seen forming biofilm-like aggregates, typically well into 
stationary phase. Thus far, these aggregates have not been shown to confer any 
advantages or disadvantages in clinical consequences; however, there are speculations 
that these aggregates may enhance the binding of the pathogen to host tissues or may 
contribute to spirochetal successful transmission to the mammalian host and to ensuing 
disease (Barbour and Hayes, 1986; Dunham-Ems et al, 2009; Merilainen et al, 2015). 
This biofilm-like aggregation may also play an important role in neuroborreliosis (Di 
Domenico, 2018). Not much has been shown conclusively to explain the mechanisms or 
purpose behind these aggregates, but it is believed that the RpoN-RpoS-LuxS pathway is 
responsible for controlling aggregate formation. Mutations in all three of these genes led 
to the formation of smaller, looser aggregates than Wild-type (Di Domenico, 2018; Sapi, 
2016). This pathway will be described in greater detail at a later point. 
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Enzootic Cycle 
B. burgdorferi exists within an enzootic cycle consisting of Ixodes tick vectors and a 
variety of hosts, including small mammals, birds, and deer. There are several species 
responsible for transmission of B. burgdorferi and Lyme disease throughout the world; 
however, the main agent for transmission in the U.S. is Ixodes scapularis, the 
blacklegged or deer tick. Infection occurs predominantly in the Northeastern and 
Midwestern U.S. with 95% of infections occurring in 14 states consisting of Connecticut, 
Delaware, Maine, Maryland, Massachusetts, Minnesota, New Hampshire, New Jersey, 
New York, Pennsylvania, Rhode Island, Vermont, Virginia, and Wisconsin (Figure 1.1A, 
1.1B). Ixodes pacificus, a species found on the Western coast of the US, has been found 
to transmit Lyme disease on rare occasions (only 1% rate of infection) (CDC, 2019). 
The cycle for Borrelia features small mammals and birds as reservoir hosts, but large 
vertebrates such as domesticated pets and humans who become infected are considered 
accidental hosts as they typically prevent both the tick and the Borrelia from continuing 
through the cycle. Because Borrelia is not transmitted transovarially, larval ticks hatch 
from the eggs borrelia-free (Figure 1.3). During the late spring and early summer, the 
larval ticks have their first blood meal. If they feed on a reservoir host containing the 
bacteria, they become a vector. After this first blood meal, the larvae drop to the ground 
and molt into nymph forms. In the following spring, the nymph has a second bloodmeal. 
The typical hosts for this bloodmeal are small mammals and birds, creating a reservoir 
host that is unaffected by the bacteria. However, humans that get bitten by the infected 
tick get infected and become accidental hosts. After this bloodmeal, the nymphal tick 
drops to the ground and molts into an adult tick. In the fall, the adult tick seeks a deer to 
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use as both a third bloodmeal and a breeding ground. After this bloodmeal, they drop to 
the ground, lay eggs, and the cycle begins again (Radolf, 2012) (Figure 1.3).  
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Figure 1.3 Enzootic Life Cycle of B. burgdorferi and Ixodes ticks 
Ixodes tick larvae hatch spirochete-free and feed on first host. Feeding on a spirochete 
reservoir host results in the creation of a Borrelia-containing tick vector. After molting 
into nymph form, a second feeding occurs which creates more reservoir hosts or an 
infection in an accidental host. The ticks then molt into adults, feed on the third host, and 
breed.  
Source: Radolf et al, 2012. 
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Lipoproteins and OspC 
The outer surface lipoproteins that make up B. burgdorferi cellular membrane are 
essential for the organism to maintain normal, if any, functionality. There are 120 
lipoprotein genes making up approximately 8% of the Borrelial genome (Fraser et al, 
1997; Haake, 2000; Setubal et al, 2006). They have a large variety of functions, including 
stimulation of inflammation and the innate immune response, acting as protective 
immunogens, and binding to tick and host molecules for colonization and dissemination 
(Kenedy et al, 2012). These are abundant in the cell and are differentially expressed 
throughout the enzootic cycle and transmission of disease (Schwan et al, 1995; Schwan 
and Piesman, 2000).  
Outer surface protein C (OspC) is a major lipoprotein expressed on the surface of 
Borrelia burgdorferi. It is differentially regulated throughout the borrelial life cycle and is 
inversely expressed with OspA. When the spirochetes are within the tick midgut prior to 
feeding, OspA is highly expressed and OspC is not expressed. Following a blood meal, 
OspA becomes downregulated and OspC becomes upregulated (Schwan et al, 1995). The 
difference in the expression of these two proteins led researchers to believe OspC is 
essential for transmission or establishment of infection. Researchers discovered that 
OspC is an antiphagocytic factor for the Borrelia. Without OspC, the bacteria were 
cleared and failed to establish infection (Carrasco et al, 2015; Grimm et al, 2004). 
Alternative sigma factors allow for the regulation of different groups of genes within 
an organism. Two important alternative sigma factors typically associated with stress 
responses in bacteria, RpoS and RpoN, were found to be directly responsible for 
controlling OspC expression in Borrelia burgdorferi (Hubner, 2001). While RpoS 
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typically acts as a stress response regulator in many bacteria, it does not in the case of B. 
burgdorferi. However, it does control the expression of key lipoproteins and virulence 
factors within the genome, including ospC, dbpA, and luxS (Caimano et al, 2004; Hubner 
et al, 2001; Sapi et al, 2016), allowing it to affect many aspects of the organism’s 
infectivity and possibly morphology. In turn, RpoS expression is directly controlled by 
alternative sigma factor 54, or RpoN, both of which are required to establish infection in 
mammals (Fisher et al, 2005; Hubner et al, 2001; Smith et al, 2007) (Figure 1.4).  
Various other proteins have been identified that help regulate this pathway. Borrelia 
oxidative stress response regulator (BosR) is a Zn-dependent transcriptional activator that 
activates rpoS transcription by binding to an upstream promoter site (Boylan et al, 2003; 
Hyde et al, 2009; Ouyang et al, 2009; Ouyang et al, 2011). It works in concert with 
response regulatory protein 2 (Rrp2), a σ54-dependent transcriptional activator, to 
transcriptionally activate RpoS expression (Blevins et al, 2009; Boardman et al, 2008; 
Burtnick et al, 2007; Yang et al, 2003). Borrelia host adaptation regulator, BadR, is more 
highly expressed in conditions similar to the midgut of unfed ticks and become 
downregulated in conditions mimicking fed ticks. This protein was the first identified 
transcriptional repressor of the RpoN-RpoS pathway (Miller et al, 2013) (Figure 1.4). 
Mutations in the BadR gene were associated with failure to colonize in mice, growth 
defects in in vitro conditions, and increases levels of RpoS, BosR, OspC, and DbpA, 
indicating its potential role as a repressor of the RpoN-RpoS pathway (Miller et al, 2013).  
Overall, the RpoN-RpoS pathway and OspC expression are regulated by external 
stimuli including temperature, CO2, cell density, pH, growth rate, and presence of blood, 
nutrients, metals, host signals. Lower temperatures, higher pH, and lower cell densities 
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are associated with the midgut of an unfed tick, at which point the RpoN-RpoS pathway 
and the associated virulence factors are downregulated. As these external stimuli shift to 
match that of a fed tick, featuring higher temperature, lower pH, and increasing cell 
densities, the expression levels of the RpoN-RpoS pathway and its targets become 
elevated (Yang et al, 2002). Despite the increasing knowledge of the pathway controlling 
OspC expression, no genetic factors have been found that link these external stimuli with 
their expression-modifying effects. 
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Figure 1.4: RpoN-RpoS Pathway Controlling OspC Expression   
The RpoN-RpoS pathway is directly responsible for controlling levels of OspC. 
Expression levels are controlled by RpoS, which in turn is directly activated by RpoN. 
This pathway has two known activators, BosR and Rrp2, and one known 
repressor,  BadR. There is currently no known factor connecting the environmental 
stimuli with this pathway.  
Source: Dr. Frank Yang 
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Transposon Mutagenesis and the Mutant Library 
Novel genetic tools have allowed researchers to delve deeper into genomic and 
proteomic studies of Borrelia. Transposon mutagenesis was used to create a mutant 
library of Borrelia burgdorferi in order to perform screening analyses. Strain B31 
contains restriction and modification enzymes on plasmids lp25 and lp56, causing 
reduced transformation efficiency. These plasmids are still required for infectivity so 
strain 5A18NP1 was engineered to contain these plasmids while lacking the 
restriction/modification enzymes, allowing for higher transformation efficiency (Stewart 
and Rosa, 2008). 
Cultures of this B. burgdorferi strain underwent transformation with an engineered 
plasmid called pGKT. This pGKT plasmid contains a mariner-based transposase 
gene, himar1, followed by a Kanamycin resistance marker (Figure 1.5B). These two 
genes are located outside of the two inverted terminal repeats that demarcate the 
transposon sequence of the plasmid. Within this transposon sequence lies a Gentamycin-
resistance marker, aacC1, and a high-copy origin of replication, ColE1 (Figure 1.5B). At 
this stage, the transposase will work to insert the plasmid into the borrelial genome at a 
random site. Upon transposition into the genome, himar1 and kan become spliced out 
while conferring Gentamycin resistance and the high-copy origin of replication, ColE1. 
This plasmid design allows for a single transposon mutagenesis to occur randomly within 
the borrelia genome (Stewart et al, 2004; Stewart and Rosa, 2008).  Using this method, a 
library of B. burgdorferi mutants could be created and used for further genetic analysis.  
Using a limiting dilution, calculated to obtain approximately 1 mutant per well, the 
samples were aliquoted into 96-well plates and grown in BSKII media. Over time, any 
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wells contain successfully transformed and mutagenized borrelia should have changed 
from red to yellow. These samples were then taken and placed into another 96-well plate. 
The library consists of 72, 96-well plates. 
Upon identification of a successful mutant transformant, the transposon sequence can 
be isolated from the mutant and transformed into E. coli, where ColE1 will enable the 
bacteria to express the gentamycin-resistance gene. Conferring gentamycin-resistance 
allows for antibiotic selection of both mutagenized borrelia sample and E. coli 
transformed with the transposon-containing plasmid. This plasmid can be isolated from 
the E. coli sample. Sequencing of the plasmid should consist of the transposon sequence 
as well as flanking regions from the borrelial genome, allowing identification of the 
transposon insertion site into the borrelial genome (Figure 1.5A) (Stewart et al, 2004; 
Stewart and Rosa, 2008).  
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Figure 1.5: Transposon Mutagenesis and the pGKT Plasmid 
A, the engineered plasmid is transformed into B. burgdorferi. The transposon is 
inserted randomly into the genome while the transposase and kan genes are spliced out. 
DNA is extracted from the mutants of interest, digested with restriction enzyme, ligated 
to form plasmids. These are transformed into E. coli to be isolated and sequenced. B, the 
pGKT plasmid engineered for creation of the mutant library. This plasmid is used in 
place of pMargent, shown in Figure 1.5A. 
Source: Stewart et al, 2004; Stewart and Rosa, 2008 
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Research Goals 
Using the extensive mutant library created by former lab members, our lab seeks to 
execute two different research goals. The first is to identify novel genes responsible for B. 
burgdorferi morphology. While some factors have been identified relating to the shape, 
movement, and aggregation of the borrelial spirochetes, there is much left to be 
understood. Furthermore, there is evidence that morphological characteristics of bacteria 
can contribute to the pathogenesis of an organism. Our aim is to observe and confirm 
morphological mutants within the mutant library and identify the genes responsible for 
the given phenotype. The phenotypes that we can expect to see are elongated, 
decrease/lack of spiral, altered motility, enhanced aggregation, slow-growing, or any 
combination of those listed. In our search for novel morphology-related genes, it is likely 
that previously identified genes will arise in this screening process. These genes include 
those described previously: flaB, flaA, flgE, fliF, fliG2, and csrA for defective spiral 
mutants; mcp, cheW, cheA, cheY, cheX, motA, and motB for motility mutants; csrA, hfq, 
and DhhP for elongated mutants; and rpoN, rpoS, and luxS for aggregate mutants. 
The second goal is to identify novel genes associated with the control of OspC 
expression. OspC has been identified as an antiphagocytic factor that is essential for 
establishing Lyme disease infection in mammals. It is in our interest to find and 
understand the mechanisms involved in regulating this protein. As discussed previously, 
the RpoN-RpoS regulatory pathway is directly responsible for OspC expression levels 
(Figure 1.4). Additional regulators, such as BadR, BosR, and rrp2, have been found to 
activate or repress this pathway. However, no links have been found between this 
pathway and the environmental stimuli that affect it. We hope to find not only novel 
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RpoN-RpoS-associated factors but genetic factors responsible for linking the external 
stimuli, such as temperature and pH, to this expression pathway.  
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MATERIALS AND METHODS 
Bacterial Strains and Culture Conditions  
Strain 5A18NP1 was engineered to lack restriction/modification enzymes found in 
B31. 5A18NP1 is the parent strain of the mutant library and is used as the Wild-type (Wt) 
sample in all experiments. BSK-II media from Barbour et al (1984) was used to culture 
B. burgdorferi. Cultures were made with or without Gentamycin and Kanamycin and at 
pH 7 or pH7.5, depending on purpose. All cultures were incubated at 37°C. Samples for 
morphology screening were grown for approximately 3 days in 1.8 mL of pH 7.5 BSKII 
with no antibiotics. After morphology checks, half of each sample was saved to make 
backstock. The remaining half was combined in 1:1 ratio with fresh BSKII (pH 7, with 
Gen and Kan) and grown for 5-7 days or until stationary phase. All stock samples of B. 
burgdorferi were stored in 15% BSKII-glycerol. DH5α competent cells were used for E. 
coli transformation. E. coli cultures were grown in LB media or on selective LB agar 
plates. 
 
Morphology Screening 
Dark field microscopy was used to observe borrelial phenotypes. All microscopy 
observations and imaging were performed at 40x using OlympusTM BX43 and 
OlympusTM CX41 microscopes. 6.8uL of sample was placed on glass microscope slide. 
Infinity AnalyzeTM was used to obtain and analyze images. Cell concentrations were 
determined by counting cells in field and multiplying by a constant of 3x105. Possible 
morphology results include elongated mutants, defective/lost spiral, decreased motility, 
increased motility, aggregates, and slow-growing mutants. 
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OspC Screening 
The samples from the morphology screenings were grown for 5-7 days until the 
samples reached stationary phase. At this point they were harvested via centrifugation at 
8000 x g for 10 minutes in a tabletop centrifuge. The supernatant was discarded, and the 
cell pellets were washed in 500 ul of 1x PBS buffer. The centrifugation and wash steps 
were repeated once. After final centrifugation, the PBS was removed, and the cell pellet 
was re-suspended in 50 ul of 1x SDS buffer. The samples were then boiled in 100°C 
water for 5 minutes. The boiled samples were spun down for 1 min to collect any 
condensation and to ensure full dissolution of the pellet. 
SDSPAGEs were performed using precast 12% polyacrylamide gels. Samples were 
loaded at 12 ul each. 3ul of ladder was loaded. Gels were run at 15 mA per gel. Gels were 
removed from casing and stained with Coomassie blue stain for 15-60 minutes. Gels were 
removed from stain and placed in de-stain buffer for 2-14 hours. Gels imaged using an 
HP Scanjet 4890 scanner. Identified mutants were tested again under differential 
conditions: pH 7-high density, pH 7.5-high density, and pH 7.5-low density. 
 
Growth Curves  
Growth curves were created by reviving samples in BSKII media. Upon reaching a 
desirable cell concentration, they were re-inoculated into 1.8mL of media at a starting 
concentration of 1x104 cells/ml. Samples were observed every day. Resulting counts are 
the averages of 10 fields of view. Statistical analysis was performed using GraphPad 
Prism 8.0TM. 
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SDS-PAGEs 
Samples were revived in 1.8 mL of pH 7.5 BSKII media. Once reaching a desirable 
concentration for re-inoculation, Borrelial samples were re-inoculated at a 1:1 ratio into 
pH 7 BSKII media containing Gentamycin and Kanamycin. Samples were grown well 
into stationary phase to induce OspC expression. Pellets were harvested by centrifugation 
at 8000 x g for 10 minutes and washed twice with 500 uL of 1x PBS buffer.  Washed 
pellets were re-suspended in 50 uL of 1x SDS buffer and placed in 100C water for 5 
minutes. Samples identified as potential OspC mutants followed this same procedure 
except they were re-inoculated under 3 different conditions: pH 7.5 high concentration, 
pH 7.5 low concentration, and pH 7.5 high concentration.   
12 uL samples for SDS-PAGEs were loaded into precast gels (Bio-Rad, 12%, 15-
well) and run at 15mA/well for approximately an hour. Gels for SDS-PAGE were 
removed from cassette and stained with 1x SDS stain for 15 minutes. Then SDS stain was 
removed and the gels were placed in de-stain buffer for approximately 2-4 hours. Images 
were obtained using desktop scanner.  
 
Cloning 
Identified mutant samples were revived in 1.8 mL of BSKII media. Upon reaching 
appropriate concentration for re-inoculation, 1 mL of sample was inoculated into 40 mL 
of BSKII containing Gentamycin and Kanamycin. Samples were grown for 
approximately 4-5 days, or until sample reaches mid to late log phase. Samples were 
harvested by centrifugation at 8000 x g for 10 minutes. Genomic DNA was extracted 
using Wizard Genomic DNA extraction kit (Promega). DNA concentrations were 
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determined using nanodrop. Using the appropriate amount of gDNA, Genomic DNA was 
digested with HindIII-HF restriction enzyme at 37°C for 2.5 hours.  
The digested product was purified using phenol-chloroform extraction. Digested 
fragments were ligated using T4 Ligase. The ligated product was transformed into 
competent DH5α E. coli cells and plated on selective LB plates containing Gentamycin. 
After overnight incubation, a colony is isolated and inoculated into 5 ml LB media and 
grown overnight. The E. coli was harvested via centrifugation and underwent miniprep 
using Thermo Fisher GeneJET Miniprep KitTM. The plasmid DNA is then sent for 
sequencing using flg and col primers. 
 
Identification of Transposon Insertion Site 
Flg and col reads contain sequences from the regions flanking the transposon 
insertion. Sequencing reads were analyzed using NCBI Blast and compared to identify 
the Tn insertion site. NCBI Blast was also used to identify the gene in which the Tn was 
inserted. 
 
Statistical Methods 
All statistical analyses were made using GraphPad Prism 8.0TM. Unpaired t-tests were 
used on all length, aggregate, and growth curve mutants. All p-values for the identified 
mutants can be found in the Results section. 
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 RESULTS 
Morphology Screening 
Former members of the lab performed multiple transposon mutagenesis procedures 
on Borrelia burgdorferi cultures and the resulting transformants were isolated and 
transferred to wells within 96-well plates. They formed a substantial mutant library 
consisting of 72 96-well plates. During the project described here, a total of 14 of these 
plates were screened resulting in approximately 1350 individual samples undergoing 
screening. From these, 85 samples have been noted as potential morphology mutants. 37 
of these samples have been double-checked and have undergone the appropriate analyses 
to confirm their phenotype, while 48 remain unconfirmed (Table 3.1).  
The potential morphology mutations are Elongated, Defective spiral, Decreased 
motility, Increased motility, Aggregate, or Slow-growing. Elongated mutants and 
aggregate mutants were identified visually and confirmed using t-tests (Figures 3.1 – 
3.4). All length measurements and statistical values for elongated mutants are detailed in 
Table 3.2. All measurements and statistical values for aggregate mutants are detailed in 
Table 3.3. Figure 3.5 shows growth curve results of several potential slow-growing 
mutants. This initial test eliminated all but six of the tested samples as potential mutants. 
These samples were initially identified as either “slow-to-grow” mutants, indicating a 
mutant that initially grew slowly but increases in growth rate partway through the curve, 
or “failure to thrive” mutants, indicating mutants that grew much more slowly throughout 
the curve and/or failed to reach stationary phase. Through statistical analysis, we 
discovered that all the “slow-to-grow” mutants (1E10, 5C2, and 48G5) were only 
statistically different from wild-type on 1 or 2 of the twelve-day curve and none of which 
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were at the beginning of the growth curve. Though the statistics marked a small 
difference, the phenotype was not strong enough for us to pursue further processing of 
these mutants. The remaining mutants (1B5, 48G9, and 52G10) had growth curves that 
clearly differed from the Wt and so were confirmed as slow-growing mutants (Figure 
3.6). 
Defective spiral mutants were defined as mutants whose spiral shape appeared 
reduced or lost. Many of the defective spiral morphologies were found in tandem with 
elongated phenotype and occasionally appeared in segments rather than throughout the 
organism. Images were obtained of these samples; however higher magnification is 
needed to perform adequate analysis on these samples (Figure 3.7). 
 Increased and decreased motility mutants are defined as mutants who appear to move 
or “twitch” at rates higher or lower than typical Wt mutants. Motility mutants have not 
yet undergone any quantitative analysis and thus are only identified on a visual basis. 
They are listed here only as a list of potential mutants. It should be noted that several 
samples have been identified as having combinations of mutant phenotypes. Thus, all 
mutants conveying any defective spiral or motility morphologies have not been fully 
confirmed, though their lengths and aggregate morphologies may have been.
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Morphology Samples Total Samples 
confirmed 
Total 
confirmed 
Samples unconfirmed Total 
unconfirmed 
Elongated 1A8, 1H12, 2D1, 2E7, 
3B5, 3D10, 3E8, 3H2, 
5D2, 5D4, 5F11, 7D8, 
7D11, 7H11, 45F12, 
45H11, 46F5, 46F10, 
47B3, 48C1, 52D9, 
52H8, 54E3, 54G1, 56E9, 
62A6, 62B2, 62C4, 62G5, 
62H4 
30 1A8, 1H12, 2D1, 
2E7, 3E8, 3H2, 
5D2, 5D4, 5F11, 
7D8, 7D11, 7H11, 
46F5, 47B3, 48C1, 
52H8, 56E9 
17 3B5, 3D10, 45F12, 45H11, 
46F10, 52D9, 54E3, 54G1, 
62A6, 62B2, 62C4, 62G5, 
62H4 
13 
Defective Spiral 3E12, 28B8, 28E12, 
62C7, 62C8  
5 N/A 0 3E12, 28B8, 28E12, 62C7, 
62C8 
5 
Decreased 
motility 
3C6, 52A11  2 N/A 0 3C6, 52A11 2 
Increased 
motility 
1E12, 2B1, 3E9, 28C4, 
45C7, 45H9, 47G11, 
56F9, 62C5, 62F6  
10 N/A 0 1E12, 2B1, 3E9, 28C4, 
45C7, 45H9, 47G11, 56F9, 
62C5, 62F6 
10 
Aggregate 1G4, 45B3, 47E11 3 1G4, 45B3, 47E11 3 N/A 0 
Slow-growing 1E10, 5C2, 7B12, 47A9, 
48H5, 54A1, 54A2  
7 1E10, 5C2, 48H5 3 7B12, 47A9, 54A1, 54A2  4 
Elongated and 
Defective spiral 
2H1, 3B4, 3E5, 3F3, 
3F10, 7F7, 7F10, 45D5, 
45D7 
9 2H1, 3F10, 45D5, 
45D7 
4 3B4, 3E5, 3F3, 7F7, 7F10  5 
Elongated and 
Aggregate 
7A10, 54G6, 54H10, 
56A12, 56D12, 62A5, 
62B6, 62C6  
8 7A10, 62A5, 62C6 3 54G6, 54H10, 56A12, 
56D12, 62B6 
5 
Elongated and 
Slow-growing 
1B5, 2C1  2 1B5 1 2C1 1 
Defective spiral 28C11, 62D5 2 N/A 0 28C11, 62D5 2 
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and Increased 
Motility 
Defective spiral 
and Decreased 
motility 
48D4 1 N/A 0 48D4 1 
Elongated, 
Defective 
Spiral, and 
Decreased 
Motility 
5G11 1 5G11 1 N/A 0 
Elongated, 
Defective 
Spiral, and 
Aggregate 
56F5, 56H2 2 56F5, 56H2 2 N/A 0 
Elongated, 
Defective 
Spiral, and 
Slow-growing 
5A7, 48G9, 52E10 3 5A7, 48G9, 52E10 3 N/A 0 
TOTAL:  85  37  48 
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Table 3.1: Identified Morphology Mutants by Type 
All potential morphology mutants categorized by type and marked as confirmed or unconfirmed. Samples that have undergone 
sequencing are listed in bold.  
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Figure 3.1: Representative Images of Elongated Mutants 
A and B, images of wild-type strain, 5A18NP1, with and without measurements. C and E, elongated mutants 1B5 and 46F10, 
without measurements. D and F, elongated mutants 1B5 and 46F10 with measurements. 
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Figure 3.2: B. burgdorferi Elongated Mutants 
Dot plot representing the length measurements, means, and SDs of the Wt (5A18NP1) and identified elongated samples. All 
samples listed were compared with the Wt samples via t-test and had p-values lower than .05. All numerical data can be found in 
Appendix A. 
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Sample Avg Length (µm) n p-value  * 
Wt 18.16 94 N/A N/A 
1A8 33.01 22 <0.0001 **** 
1B5 29.50 38 <0.0001 **** 
1H12 52.40  5 <0.0001 **** 
2D1 55.26 6 <0.0001 **** 
2E7 35.07 6 <0.0001 **** 
2H1 57.49 9 <0.0001 **** 
3E8 23..47 10   .0100 * 
3F10 51.63 13 <0.0001 **** 
3H2 43.87 11 <0.0001 **** 
5A7 108.1 3 <0.0001 **** 
5D2 35.47 6 <0.0001 **** 
5D4 31.03 17 <0.0001 **** 
5F11 32.99 5 <0.0001 **** 
5G11 27.76 7 .0003 *** 
7A10 181.4 6 <0.0001 **** 
7D8 59.96 5 <0.0001 **** 
7D11 75.89 3 <0.0001 **** 
47B3 22.98 20 .0011 ** 
45D5 47.82 5 <0.0001 **** 
45D7 41.69 14 <0.0001 **** 
46F5 43.99 15 <0.0001 **** 
48C1 50.83 19 <0.0001 **** 
48G9 43.66 14 <0.0001 **** 
52E10 49.95 10 <0.0001 **** 
52H8 48.57 28 <0.0001 **** 
56E9 40.61 14 <0.0001 **** 
56F5 29.29 56 <0.0001 **** 
56H2 35.08 33 <0.0001 **** 
62A5 30.83 89 <0.0001 **** 
62C6 36.05 16 <0.0001 **** 
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Table 3.2: Measurements and P-values for Elongated Mutants 
All elongated mutants were measured using Infinity AnalyzeTM and statistics analyses 
were performed using GraphPad Prism 8.0.  
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Figure 3.3: Representative Images of Aggregate Mutants 
A and B, images of wild-type strain, 5a18NP1, with and without measurements. C and E, aggregate mutant strains 1G4 and 47E11 
without measurements. D and F, aggregate mutant strains 1G4 and 47E11 with measurements.  
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Figure 3.4: B. burgdorferi Aggregate Mutants 
Dot plot representing the measurements, means, and SDs of the diameters of the 
Borrelial aggregates. All samples listed were compared with Wt (5A18NP1) via t-test. 
Not all samples had p-values lower than .05. Samples considered significant are marked 
with * and **. All numerical data can be found in Appendix A. 
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Sample Diameter (um) n P-value * 
Wt 7.19 3 N/A N/A 
1A8 9.28 2 .3914 N/A 
1B5 19.86 2 .0342 * 
1G4 18.83 2 .0086 ** 
3F10 13.16 2 .1557 N/A 
3H2 9.88 2 .2684 N/A 
7D9 14.84 6 .1250 N/A 
45B3 27.12 4 .0023 ** 
47B5 19.10 8 .0643 N/A 
47E11 31.34 6 .0133 * 
56F5 15.43 6 .0436 * 
62A5 19.90 8 .0158 * 
62C6 15.92 14 .1021 N/A 
 
  
 48 
Table 3.3: Measurements and P-values of Aggregate Mutants 
All aggregate mutants were measured using Infinity AnalyzeTM and statistics analyses 
were performed using GraphPad Prism 8.0.  
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Figure 3.5: Potential B. burgdorferi Growth Mutants 
Growth curve data of all samples originally identified as slow-growing mutants. Not 
all samples tested presented mutant phenotype. Slow-growing mutants identified from 
this experiment are represented in individual growth curves in Figure 3.4. 
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Figure 3.6: Individual Growth Curves of Slow-Growing Mutants 
The growth curves of the possible slow-growing mutants were isolated from the curves in Figure 3.3. From these we identified 
which samples showed strong slow-growing phenotype. Samples 1B5, 48G9, and 52E10 differ significantly from the Wt curve and is 
the most noticeable during the mid- to late-stages of the curve. 1E10, 5C2, and 48H5, however, are only noted to be statistically 
different on Days 9 and 10, which does not match our proposed “slow-to-grow” phenotype. 
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Figure 3.7: Representative Images of Defective Spiral Mutants 
A, Image of wild-strain, 5A18NP1. B-F, images of potential defective spiral mutants 2E7, 7F7, 45D5, 48G9, and 52E10, 
respectively. 
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OspC Screening 
SDS-PAGEs were used to run preliminary screenings on all the mutant library 
samples. Figure 3.8 shows the SDS-PAGEs run on Plate 46 to represent the screenings 
run on all the mutant library plates. Only one OspC expression mutant, 46A2, was found 
from this plate and was marked as a complete OspC deficient mutant. From all of the 
screenings, 66 potential OspC expression mutants were found. Of these, 13 were 
identified as complete knockouts of OspC expression while 22 and 31 were identified as 
underexpressed and overexpressed, respectively (Table 3.4). Because the focus in this 
experiment has been on those samples completely lacking OspC expression, the 
underexpressed and overexpressed samples have not yet been confirmed. 8 of the 13 
mutants proposed to be lacking OspC were re-grown and the SDSPAGES were repeated 
(Table 3.4; Figure 3.9). The samples 28C2, 28F7, 45C4, 46A2, 52G11, and 56H11 were 
confirmed complete OspC deficient mutants. 45B3 and 52G10 have also been confirmed 
as lacking OspC; however, they were not run in the procedure shown in Figure 3.9.  
Of the confirmed OspC depleted mutants, 6 samples had undergone conditional SDS-
PAGE in which they were grown in different pH’s (7 and 7.5) and to different 
concentrations (low and high) in order to further affirm their mutant OspC expression 
(Figure 3.10). Due to the effects of differing pH and cell densities on OspC expression 
levels in Wt, three conditions are used to confirm OspC expression phenotype. Low cell-
density and higher pH (7.5) is used somewhat like a negative control, high cell density 
with pH 7.5 matches standard culture conditions, and high cell density with lower pH (7) 
is used to enhance OspC expression. Samples 52G10, 52G11, and 56H11 were 
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successfully tested under these conditions and showed clear depletion of OspC, while 
samples such as 52B7, 52F1, and 52F11 did not (Figure 3.10). 
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OspC 
Expression 
Samples Total Samples 
confirmed 
Total 
confirmed 
Samples unconfirmed Total 
unconfirmed 
No expression 28C2, 28F7, 45B3, 45C4, 
45F5, 46A2, 52G10, 
52G11, 56H11, 62A2, 
62B3, 62E3, 62H5 
13 28C2, 28F7, 
45B3, 45C4, 
46A2, 52G10, 
52G11, 56H11  
8 45F5, 62A2, 62B3, 62E3, 
62H5 
5 
Underexpression 1F5, 3F10, 45A5, 45B11, 
45B12, 45C2, 45C8, 
45C9, 45D1, 45E7, 45E9, 
45E11, 45H4, 47A6, 
47B5, 47D11, 47E5, 
47F1, 47F6, 48H12, 
56D1, 56G5 
22 N/A N/A 1F5, 3F10, 45A5, 45B11, 
45B12, 45C2, 45C8, 45C9, 
45D1, 45E7, 45E9, 45E11, 
45H4, 47A6, 47B5, 47D11, 
47E5, 47F1, 47F6, 48H12, 
56D1, 56G5 
22 
Overexpression 1D12, 2A6, 2A9, 2A10, 
2A12, 2B6, 2B11, 2B12, 
2D12, 2G11, 2H7, 2H12, 
3B2, 3D2, 3D3, 3F12, 
3H3, 28A8, 28C4, 28G9, 
45B2, 45C7, 45C10, 
52D1, 52D12, 52E12, 
52G7, 62B4, 62F3, 62F4, 
62H1 
31 N/A N/A 1D12, 2A6, 2A9, 2A10, 2A12, 
2B6, 2B11, 2B12, 2D12, 
2G11, 2H7, 2H12, 3B2, 3D2, 
3D3, 3F12, 3H3, 28A8, 28C4, 
28G9, 45B2, 45C7, 45C10, 
52D1, 52D12, 52E12, 52G7, 
62B4, 62F3, 62F4, 62H1 
 
31 
Total  66  8  58 
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Table 3.4: List of OspC Expression Mutation Types and Identified Samples 
All of the potential OspC mutants are listed according their mutation type. Confirmed 
mutants had undergone secondary SDSPAGE testing while unconfirmed mutants have 
not. Because the focus was on complete OspC knockouts, only these have undergone 
confirmatory testing thus far. Samples that have undergone sequencing are listed in bold.  
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Plate 46  
     lad    Wt   A1  A2   A3   A4   A5   A6  A7   A8  A9  A10 A11 A12  B1          B2  lad   B3   B4   B5  B6  B7   B8   B9 B10 B11 B12 C1   C2  C3           C4    C5   lad  C6  C7   C8  C9  C10 C11 C12  D1  D2  D3   D4   D5    
 
 
     D6   D7  D8  lad   D9 D10 D11 D12 E1   E2   E3   E4  E5   E6    E7            lad   Wt    E8 E10  E11 E12   F1   F2   F3    F4   F5   G6  G11 H5 H10 
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Figure 3.8: SDS-PAGEs of Plate 46 Samples 
Preliminary OspC screening of samples from Plate 46 via SDS-PAGE. These are 
representative of the screenings performed on all of the samples within the OspC 
screening process.
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     3       28                 45              46   47  52   56  
   lad Wt C8  C2  F7  B3 B8 C4 D4  E4 A2 F4 G11 H11 
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Figure 3.9: SDS-PAGE of Potential OspC Deficient Mutants 
The potential OspC mutants were regrown and used in a second SDS-PAGE to verify 
OspC-lacking phenotype. Samples 3C8, 45B8, 45D4, 45E4, and 47F4 identified as false 
mutants, however 47F4 may be underexpressed. The remaining samples were confidently 
labeled as OspC deficient mutants.  
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   Lad      5A18NP1    52B7              52F1            52F11   
pH  7     7.5   7.5   7    7.5  7.5    7    7.5   7.5    7    7.5  7.5 
Conc.             H     L     H    H     L    H     H     L     H     H    L     H  
 
       5A18NP1          52G10         52G11       56H11   
pH       7     7.5   7.5   7    7.5  7.5    7    7.5   7.5    7    7.5  7.5 
Conc.       H     L     H    H     L    H     H     L     H     H    L     H  
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Figure 3.10: Conditional SDS-PAGEs of Potential OspC-Lacking Mutants 
Samples were checked under three different conditions. Low-density, pH 7.5 samples 
act as negative controls because they are sub-optimal for OspC expression. High-density, 
pH 7 samples are the most optimal for OspC expression and thus act as a positive control. 
High-density, pH 7.5 samples are representative of conditions similar to in vivo 
conditions. Samples 52B7, 52F1, and 52F11 were found to be false mutants while 
52G10, 52G11, and 56H11 were confirmed.  
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Sequencing and Identification of Tn Insertion Site 
Identified and confirmed mutants from both screens underwent cloning in order to 
obtain the plasmid containing the transposon insertion site. The plasmids were 
transformed into DH5alpha competent cells and grown on selective plating to obtain 
isolated colonies. The plasmid was obtained from these colonies and sent out for 
sequencing using Col and Flg primers. The insertion should have entered into one 
position in the genome, and the sequencing data points to the insertion site of the 
transposon sequence. Eleven samples, 4 morphology mutants and 7 OspC mutants, were 
successfully sequenced and identified (Table 3.5). 
Most of the morphology mutants resulted in novel genes. 7A10, 48C1, and 56H2 had 
mutations in BB_0043, BB_0420, and BB_0811, respectively. All three of which were 
previously unstudied hypothetical proteins (Table 3.5, Figure 3.11 A-C). Further studies 
will need to be conducted to characterize these genes and their association with borrelial 
morphology. The mutated gene in 52H8 was surface-located membrane protein 1, LMP1 
(Table 3.5, Figure 3.11D). Previous studies have identified this as a membrane protein 
required to resist or evade the host-adaptive immune response, but none of these studies 
compared morphologies or noted morphological mutants during their work (Kenedy et al, 
2012; Koci et al, 2018; Yang et al, 2009; Yang et al, 2010).   
Four of the seven OspC mutants contained mutations within the OspC gene itself 
(Table 3.5; Figure 3.11H). The remaining three OspC mutant samples resulted in unique 
genes, however. Mutations were found in fibronectin-binding protein gene bbk32, 
adenine deaminase gene bbk17 or adeC, and ribonuclease HII gene rnhB (Table 3.5; 
Figure 3.11 E-G) resulting in depleted OspC expression. The BBK32 protein has already 
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been extensively studied and identified a surface protein that is important for enhancing 
infectivity potential in B. burgdorferi and is regulated by the Rrp2-RpoN-RpoS pathway 
(He et al, 2007; Seshu et al, 2006). However, current studies have only suggested that it 
is co-regulated with OspC. None so far have studied whether BBK32 plays any role in 
controlling OspC levels.  
Bbk17, or adeC, has also been shown to contribute to mammalian infectivity (Jewett 
et al, 2007). It encodes an adenine deaminase and is required for the direct deamination 
of adenine to hypoxanthine, a purine important for the salvage of adenine in many 
prokaryotic species (Jewett et al, 2007; Nygaard et al, 1996). Unlike BBK32, the 
mechanisms controlling AdeC levels have not yet been studied. The protein’s affiliation 
with the RpoN-RpoS pathway and OspC regulation remain to be seen. The product of the 
third gene, rnhB, was determined based off of sequence homology (Fraser et al, 1997), 
but no further studies have been conducted to characterize the gene or its protein product. 
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Sample 
ID 
Phenotype Confirmation Gene ID Gene 
Name 
Gene Product Insertion 
Site 
7A10 Elongated, aggregate Via imaging and 
statistical analysis 
BB_0043 unnamed Unknown, predicted protein 
coding gene 
42392, 
42393 
48C1 Elongated Via imaging and 
statistical analysis 
BB_0420 unnamed Sensory transduction 
histidine kinase, putative 
433448, 
433449 
52H8 Elongated Via imaging and 
statistical analysis 
BB_0210 LMP1 Surface-located membrane 
protein 1 
212916, 
212917 
56H2 Elongated, defective 
spiral, aggregate 
Via imaging and 
statistical analysis 
BB_0811 unnamed Conserved hypothetical 
protein 
858615, 
858616 
28F7 Complete OspC 
deficiency  
Via repeated SDS-
PAGE 
BB_K32 bbk32 Fibronectin-binding protein 21036, 
21037 
45B3 Complete OspC 
deficiency 
Via repeated SDS-
PAGE 
BB_B19 OspC Outer surface protein C 17213, 
17214 
45C4 Complete OspC 
deficiency 
Via repeated SDS-
PAGE 
BB_K17 bbk17 Adenine deaminase C 11791, 
11792 
46A2 Complete OspC 
deficiency 
Via repeated SDS-
PAGE 
BB_0046 rnhB Ribonuclease HII 45787, 
45788 
52G10 Complete OspC 
deficiency 
Via repeated SDS-
PAGE 
BB_B19 OspC Outer surface protein C 16946, 
16947 
52G11 Complete OspC Via repeated SDS- BB_B19 OspC Outer surface protein C 16946, 
  
6
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6
9
 
deficiency PAGE 16947 
56H11 Complete OspC 
deficiency 
Via repeated SDS-
PAGE 
BB_B19 OspC Outer surface protein C 16946, 
16947 
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Table 3.5: List of Sequenced Samples and their Transposon Insertion Sites 
All samples to be successfully cloned and sequenced, with morphology mutants listed first followed by OspC mutants. Imaging 
and statistical analysis can be found in the Morphology Screening section. SDS-PAGEs can be found in the OspC screening section. 
Gene ID refers to the original name/location of the gene according to the sequencing performed in strain B31.   
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Figure 3.11: Transposon Insertion Sites of Sequenced Mutants 
Col and flg reads were used with NCBI Blast to identify flanking regions of the 
transposon sequence. A-D, sequenced morphology mutants. E-H, sequenced OspC 
expression mutants. E-G: 28F7, 45C4, and 46A2 are indicated in red in the 
accompanying SDS-PAGE image. Multiple OspC expression mutants contained 
mutations in the ospC gene. 52G10 represents the sequencing results for these mutants. 
52G11 and 56H11 had transposon insertion sites identical to 52G10. 
  
 80 
 
DISCUSSION 
 
From screening of approximately 1350 mutagenized samples, 85 potential 
morphology mutants and 66 potential OspC expression mutants have been found. While 
not all of these have a confirmed phenotype, they lay the groundwork for future 
investigations. The unconfirmed elongated, aggregate, and/or slow-growing mutants can 
undergo further microscopy analyses to provide visual and statistical evidence to their 
phenotypes. While only 40x magnification was used in this procedure, further endeavors 
can include higher magnification or enhanced microscopy procedures to characterize 
potential defective spiral mutants. Swarm agar assays in BSKII agar can be used to obtain 
quantifiable comparisons between Wt and potential motility mutants. 
Of the OspC expression mutants, the main focus of the study was to identify mutants 
with complete OspC depletion. With over half of the OspC depleted mutants containing 
transposon insertions in the ospC gene itself (Table 3.5), the focus may shift to those with 
underexpressed or overexpressed OspC phenotypes. Further work will be conducted to 
verify the OspC expression phenotypes of the remaining OspC depleted mutants as well 
as the underexpressed and overexpressed phenotypes. This work includes repeated SDS-
PAGEs and conditional SDS-PAGEs. 
Of the 37 confirmed morphology mutants and the 8 confirmed OspC expression 
mutants, eleven samples have been successfully identified, cloned, and sequenced, 
resulting in the identification of both novel and previously discovered genes. As detailed 
earlier, three of the morphology mutants resulted in putative/hypothetical proteins (Table 
3.5). These samples will undergo complementation to confirm the relationship between 
the gene and its observed phenotype. Plasmid profiling will be used to confirm the 
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observed phenotypes are not due to loss of any plasmids. Upon confirmation of genotypic 
link to the phenotype, studies should be performed to characterize the structure of the 
protein and potential biochemical interactions. Information obtained from these studies 
may help determine how these proteins function and produce the observed phenotype 
within the organism. 
LMP1, the mutated gene in 52H8 (Table 3.5, Figure 3.11D), has been identified in 
other studies as a membrane protein required to resist or evade the host-adaptive immune 
response (Kenedy et al, 2012; Koci et al, 2018; Yang et al, 2009; Yang et al, 2010). 
However, none of these studies compared morphologies or noted morphological mutants 
during their work. As morphologies of B. burgdorferi can be affected by various changes 
in environment, such as inadequate nutritional media (Barbour et al, 1986), careful 
analysis of morphology is suggested while continuing knock-out/complementation work 
on this gene.  
The four identified genes from the OspC depleted mutants consist of bbk32, bbk17 
(also known as adeC), rnhB, and ospC. The BBK32 protein has already been extensively 
studied and identified as a surface protein of B. burgdorferi that plays an important role 
in the attachment of the spirochetes to the extracellular matrix and is required for optimal 
infectivity of the organism (Fischer et al, 2006; Hyde et al, 2011b; Probert and Johnson, 
1998). It is more highly expressed during tick feeding and mammalian infection and has 
lower expression in flat, unfed ticks (Fikrig et al, 2000; Li et al, 2006). More importantly, 
it has been found to illicit protective host immune activity and its inactivation decreases 
the infectivity of B. burgdorferi (Fikrig et al, 1997; Seshu et al, 2006). The combination 
of all these factors led to the discovery that BBK32 is in fact controlled by the Rrp2-
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RpoN-RpoS pathway alongside OspC (He et al, 2007). While the mechanisms 
controlling for BBK32 have been studied, no studies have been performed to identify if 
BBK32 controls expression of OspC. Experiments should be performed to distinguish if 
the loss of OspC is indeed controlled by loss of BBK32. If so, further experimentation 
should be done to determine the molecular processes behind this control. 
BBK17 has also been previously studied, though not to the extent of BBK32. BBK17, 
or adeC, was identified as an important contributor to mammalian infectivity and its 
inactivation attenuates B. burgdorferi infection in mice (Jewett et al, 2007). Unlike 
BBK32, no connection has been made between adeC and the RpoN-RpoS pathway. It has 
so far only been characterized as an adenine deaminase required for the direct 
deamination of adenine to produce hypoxanthine, a purine derivative important for the 
salvage and metabolism of adenine in many prokaryotic species (Jewett et al, 2007; 
Nygaard et al, 1996). Hypoxanthine is the most abundant purine in mammalian blood and 
its transport may be critical during the initial stages of Borrelial infectivity (Hartwick et 
al, 1979; Jain et al, 2012). Further studies would need to be performed in order to 
establish a relationship between adeC and the OspC expression phenotype, to establish a 
relationship between adeC and the RpoN-RpoS pathway, and to identify any effects of 
adeC on infectivity and pathogenesis of the organism.  
The third gene found associated with depleted OspC expression was rnhB, 
ribonuclease HII, that has been predicted to specifically degrade the RNA of RNA-DNA 
hybrids (Ohtani et al, 1999). The gene product and its function in B. burgdorferi has so 
far only been predicted from sequence homology (Fraser et al, 1997) and has not been 
studied further. Ribonucleases have a wide variety of potential functions involving 
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bacterial RNA metabolism, such as switching pre-RNA to functional RNAs, mRNA 
regulation, mRNA degradation, or controlling regulatory RNAs (Deutscher, 2006; 2015; 
Esquerre et al, 2014). Ribonuclease HII, or RNase HII, is a temperature-sensitive enzyme 
whose activity is dependent on the presence of Mn2+ (Ohtani et al, 1999). This is 
particularly intriguing as Mn2+ plays a critical role in the regulation of the RpoS pathway 
controlling OspC expression (Troxell et al, 2013). However, it should be noted that 
activity of RNase HII is positively correlated with the presence of Mn2+ while the 
presence of Mn2+ is inversely correlated with the presence of OspC. This makes our 
findings particularly confusing as the loss of RNase HII results in depletion of OspC. 
In terms of physiological roles, RNase H’s have been widely studied in E. coli but 
with stronger focus on RNase HI as opposed to RNase HII. Thus far, researchers have 
hypothesized that RNase HII is responsible for excising misincorporated ribonucleotides 
in DNA as a type of DNA repair (Rydberg and Game, 2002). This role may hold true in 
some cases, but it does not adequately explain the link between the enzyme and OspC 
expression seen here. RNase HII is also believed to constitute a significant part of the 
RNA degradosome complex in E. coli. Its primary role appears to be the degradation of 
mRNA (Lu and Taghbalout, 2014). It is possible that RNase HII holds a similar role in B. 
burgdorferi, either on its own or in conjunction with a previously undiscovered 
degradosome complex, in order to aid in RNA processing and/or degradation.  
As with the rest of the identified genes, complementation would be used to ensure a 
link between the observed phenotype and the rnhB gene. With the tendency for RNases 
to regulate gene expression, this gene will be particularly interesting to explore in relation 
to RpoN, RpoS, and OspC levels. Due its strong association with other degradosome 
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proteins in E. coli, it may be a good idea to search for other degradosome proteins present 
in B. burgdorferi. Any that are found should be analyzed for associations with RNase HII 
and effects on OspC expression. Immunofluorescence experiments would be 
recommended regardless of the presence of other degradosome proteins in order to 
identify which factors in the RpoN-RpoS pathway may be affected by this enzyme. 
Studies should be performed to characterize biochemical and molecular interactions of 
this enzyme that effect this pathway. 
For all identified mutants, procedures such as Western blots and plasmid profiling 
would be necessary to confirm the causal relationship of the genotype to the phenotype. 
Using complementation procedures with Western blotting would allow for evaluation of 
the role of the identified gene in relation to its protein expression. Plasmid profiling is an 
essential step in verifying a genotype-phenotype link due to B. burgdorferi’s spontaneous 
loss of plasmids when growing in vitro. This process allows us to visualize all the 
plasmids present within the sample compared to wildtype and allows us to verify that the 
observed phenotype is not due to a missing plasmid. The plasmid profiling process can 
also lead to novel discoveries involving plasmids, rather than genes, found responsible 
for certain phenotypes. For example, preliminary data from Dr. Raghunandanan in the 
Yang Lab has shown that at least three OspC deficient mutants are missing plasmid lp21. 
Additionally, the genes identified from sequencing did not return Wt phenotype after 
complementation. This discovery is intriguing as lp21 has previously been thought to be 
unnecessary.  
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APPENDIX A:  List of All Potential Mutants by Plate Number 
Sample Phenotype Confirmation Insertion Site/Gene 
Plate 1 
1A8 Elongated Via imaging and stats analysis n/a 
1B5 Elongated and slow-growing Via imaging, growth curves, and stats 
analysis 
n/a 
1D12 OspC Overexpression Unconfirmed n/a 
1E10 Slow-growing Via growth curves and stats analysis n/a 
1E12 Increased motility Unconfirmed n/a 
1F5 OspC Underexpression Unconfirmed n/a 
1G4 Aggregate Via imaging and stats analysis n/a 
1H12 Elongated Via imaging and stats analysis n/a 
Plate 2 
2A6 OspC Overexpression Unconfirmed n/a 
2A9 OspC Overexpression Unconfirmed n/a 
2A10 OspC Overexpression  Unconfirmed n/a 
2A12 OspC Overexpression Unconfirmed n/a 
2B1 Increased motility Unconfirmed n/a 
  
 
8
6
 
2B6 OspC Overexpression Unconfirmed n/a 
2B11 OspC Overexpression Unconfirmed n/a 
2B12 OspC Overexpression Unconfirmed n/a 
2C1 Elongated and slow-growing Unconfirmed n/a 
2D1 Elongated Via imaging and stats analysis n/a 
2D12 OspC Overexpression Unconfirmed n/a 
2E7 Elongated Via imaging and stats analysis n/a 
2G11 OspC Overexpression Unconfirmed n/a 
2H1 Elongated and defective spiral Via imaging and stats analysis n/a 
2H7 OspC Overexpression Unconfirmed n/a 
2H12 OspC Overexpression Unconfirmed n/a 
Plate 3 
3B2 OspC Overexpression Unconfirmed n/a 
3B4 Elongated and defective spiral Unconfirmed n/a 
3B5 Elongated Unconfirmed n/a 
3C6 Decreased motility Unconfirmed n/a 
3D2 OspC Overexpression Unconfirmed n/a 
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3D3 OspC Overexpression Unconfirmed n/a 
3D10 Elongated Unconfirmed n/a 
3E5 Elongated and defective spiral Unconfirmed n/a 
3E8 Elongated Via imaging and stats analysis n/a 
3E9 Increased motility Unconfirmed n/a 
3E12 Defective spiral Unconfirmed n/a 
3F3 Elongated and defective spiral Unconfirmed n/a 
3F10 Elongated and defective spiral 
OspC Underexpression 
Via imaging and stats analysis 
Unconfirmed 
n/a 
3F12 OspC Overexpression Unconfirmed n/a 
3H2 Elongated Via imaging and stats analysis n/a 
3H3 OspC Overexpression  Unconfirmed n/a 
Plate 5 
5A7 Elongated, defective spiral, slow-
growing 
Via imaging and stats analysis; Slow-growth 
phenotype unconfirmed 
n/a 
5C2 Slow-growing Via growth curve and stats analysis n/a 
5D2 Elongated Via imaging and stats analysis n/a 
5D4 Elongated Via imaging and stats analysis n/a 
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5F11 Elongated Via imaging and stats analysis n/a 
5G11 Elongated, defective spiral, and 
decreases motility 
Via imaging and stats analysis; Motility 
phenotype unconfirmed 
n/a 
Plate 7 
7A10 Elongated and aggregate Via imaging and stats analysis BB_0043: unknown predicted protein 
coding gene 
7B12 Slow-growing Unconfirmed n/a 
7D8 Elongated Via imaging and stats analysis n/a 
7D11 Elongated Via imaging and stats analysis n/a 
7F7 Elongated and defective spiral Unconfirmed n/a 
7F10 Elongated and defective spiral Unconfirmed n/a 
7H11 Elongated Via imaging and stats analysis n/a 
Plate 28 
28A8 OspC Overexpression Unconfirmed n/a 
28B8 Defective spiral Unconfirmed n/a 
28C2 Complete OspC deficiency Via repeated SDS-PAGE n/a 
28C4 Increased motility 
OspC Overexpression 
Unconfirmed 
Unconfirmed 
n/a 
  
 
8
9
 
28C11 Defective spiral Unconfirmed n/a 
28E12 Defective spiral Unconfirmed n/a 
28F7 Complete OspC deficiency  Via repeated SDS-PAGE Bbk32: Fibronectin-binding protein 
28G9 OspC Overexpression Unconfirmed n/a 
Plate 45 
45A5 OspC Underexpression Unconfirmed n/a 
45B2 OspC Overexpression Unconfirmed n/a 
45B3 Aggregate 
Complete OspC deficiency 
Via imaging and stats analysis 
Via repeated SDS-PAGE 
BB_B19: Outer surface protein C 
45B11 OspC Underexpression Unconfirmed n/a 
45B12 OspC Underexpression Unconfirmed n/a 
45C2 OspC Underexpression Unconfirmed n/a 
45C4 Complete OspC deficiency Via repeated SDS-PAGE BB_K17: Adenine deaminase C 
45C7 Increased motility 
OspC Overexpression 
Unconfirmed 
Unconfirmed 
n/a 
45C8 OspC Underexpression Unconfirmed n/a 
45C9 OspC Underexpression Unconfirmed n/a 
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45C10 OspC Overexpression Unconfirmed n/a 
45D1 OspC Underexpression Unconfirmed n/a 
45D5 Elongated and defective spiral Via imaging and stats analysis n/a 
45D7 Elongated and defective spiral Via imaging and stats analysis n/a 
45E7 OspC Underexpression Unconfirmed n/a 
45E9 OspC Underexpression Unconfirmed n/a 
45E11 OspC Underexpression Unconfirmed n/a 
45F5 Complete OspC deficiency Unconfirmed n/a 
45F12 Elongated Unconfirmed n/a 
45H4 OspC Underexpression Unconfirmed n/a 
45H9 Increased motility Unconfirmed n/a 
45H11 Elongated Unconfirmed n/a 
Plate 46 
46A2 Complete OspC deficiency Via repeated SDS-PAGE BB_0046: Ribonuclease HII 
46F5 Elongated Via imaging and stats analysis n/a 
46F10 Elongated Via imaging and stats analysis n/a 
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Plate 47 
47A6 OspC Underexpression Unconfirmed n/a 
47A9 Slow-growing Unconfirmed n/a 
47B3 Elongated Via imaging and stats analysis n/a 
47B5 OspC Underexpression Unconfirmed n/a 
47D11 OspC Underexpression Unconfirmed n/a 
47E5 OspC Underexpression Unconfirmed n/a 
47E11 Aggregate Via imaging and stats analysis n/a 
47F1 OspC Underexpression Unconfirmed n/a 
47F6 OspC Underexpression Unconfirmed n/a 
47G11 Increased motility Unconfirmed n/a 
Plate 48 
48C1 Elongated Via imaging and stats analysis BB_0420: Sensory transduction 
histidine kinase, putative 
48D4 Defective spiral and decreased 
motility 
Unconfirmed n/a 
48G9 Elongated, defective spiral, and 
slow-growing 
Via imaging, growth curves, and stats 
analysis 
n/a 
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48H5 Slow-growing Via growth curves and stats analysis n/a 
48H12 OspC Overexpression Unconfirmed n/a 
Plate 52 
52A11 Decreased motility Unconfirmed n/a 
52D1 OspC Overexpression Unconfirmed n/a 
52D9 Elongated Unconfirmed n/a 
52D12 OspC Overexpression Unconfirmed n/a 
52E10 Elongated, defective spiral, and 
slow-growing 
Via imaging, growth curve, and stats analysis n/a 
52E12 OspC Overexpression Unconfirmed n/a 
52G10 Complete OspC deficiency Via repeated SDS-PAGE BB_B19: Outer surface protein C 
52G11 Complete OspC deficiency Via repeated SDS-PAGE BB_B19: Outer surface protein C 
52H8 Elongated Via imaging and stats analysis BB_0210: LMP1, surface-located 
membrane protein 1 
Plate 54 
54A1 Slow-growing Unconfirmed n/a 
54A2 Slow-growing Unconfirmed n/a 
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54E3 Elongated Unconfirmed n/a 
54G1 Elongated Unconfirmed n/a 
54G6 Elongated and aggregate Unconfirmed n/a 
54H10 Elongated and aggregate Unconfirmed n/a 
Plate 56 
56A12 Elongated and aggregate Unconfirmed n/a 
56D12 Elongated and aggregate Unconfirmed n/a 
56E9 Elongated Via imaging and stats analysis n/a 
56F5 Elongated, defective spiral, and 
aggregate 
Via imaging and stats analysis n/a 
56F9 Increased motility Unconfirmed n/a 
56H2 Elongated, defective spiral, 
aggregate 
Via imaging and statistical analysis BB_0811: Conserved hypothetical 
protein 
56H11 Complete OspC deficiency Via repeated SDS-PAGE BB_B19: Outer surface protein C 
Plate 62 
62A2 Complete OspC deficiency Unconfirmed n/a 
62A5 Elongated and aggregate Via imaging and stat analysis n/a 
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62A6 Elongated Unconfirmed n/a 
62B2 Elongated Unconfirmed n/a 
62B3 Complete OspC deficiency Unconfirmed n/a 
62B4 OspC Overexpression Unconfirmed n/a 
62B6 Elongated and aggregate Unconfirmed n/a 
62C4 Elongated Unconfirmed n/a 
62C5 Increased motility Unconfirmed n/a 
62C6 Elongated and aggregate Via imaging and stats analysis n/a 
62C7 Defective spiral Unconfirmed n/a 
62C8 Defective spiral Unconfirmed n/a 
62D5 Defective spiral and increased 
motility 
Unconfirmed n/a 
62E3 Complete OspC deficiency Unconfirmed n/a 
62F3 OspC Overexpression Unconfirmed n/a 
62F4 OspC Overexpression Unconfirmed n/a 
62F6 Increased motility Unconfirmed n/a 
62G5 Elongated Unconfirmed n/a 
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62H1 OspC Overexpression Unconfirmed n/a 
62H4 Elongated Unconfirmed n/a 
62H5 Complete OspC deficiency Unconfirmed n/a 
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